Clopid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopid

Quick Facts

Property Description
Active Ingredient Clopidogrel (as bisulfate salt)
Form Film-coated tablet
Pharmacological Class Antiplatelet Agent (P2Y12 Inhibitor)
Origin / Type Synthetic Prodrug (Thienopyridine Derivative)
Prescription Status Prescription-only (Rx)
General Purpose Reduction of unwanted blood clot formation

1. Identity and Composition: What Type of Medicine is Clopid?

Clopid is an oral medication that contains the active ingredient Clopidogrel, which is classified as an antiplatelet agent, specifically a thienopyridine derivative. This prescription-only substance is synthetic in origin and is supplied as a single-ingredient, film-coated tablet intended for oral administration.

Clopidogrel is distinguished as a prodrug, meaning the substance itself is largely inactive upon ingestion and must undergo metabolic conversion by liver enzymes, principally CYP2C19, to produce its therapeutically active metabolite. This characteristic, where genetic variations in the activating enzyme can influence its action, is a recognized factor in its clinical use. The active ingredient is included on the list of essential medicines, reflecting its broad recognition for managing cardiovascular conditions.


2. General Purpose and Physiological Effect

The core function of Clopidogrel is to reduce the ability of blood platelets to stick together and form unwanted clots in the arteries. Its active metabolite achieves this by irreversibly binding to the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface, preventing the molecular signaling that triggers aggregation.

This antiplatelet action is used for preventing the formation of atherothrombotic events—serious blockages caused by blood clots in diseased blood vessels. The sustained platelet inhibition provided by Clopidogrel is used in patient scenarios where maintaining unobstructed blood flow is a central requirement, reducing the chance that a harmful blood clot will form.

Regulatory References

  1. Clopidogrel Pharmacogenetics - ClinPGx
  2. Clopidogrel - WHO Essential Medicines List
  3. Clopidogrel - Mechanism of Action (StatPearls)

What side effects are possible with Clopid?

Possible Side Effects and Safety Information

The safety profile for Clopidogrel is primarily characterized by the risk of bleeding events, which are explicitly documented by government regulatory agencies. All listed side effects and safety restrictions are derived exclusively from official prescribing information.

Documented Adverse Reactions

The most commonly reported adverse event with clinical significance is bleeding, ranging from minor to life-threatening. Adverse reactions are classified by frequency as follows:

Frequency Category Examples of Officially Listed Adverse Reactions
Common Hematoma (bruising), Epistaxis (nosebleed), Gastrointestinal hemorrhage, Diarrhea, Abdominal pain
Uncommon Intracranial hemorrhage, Nausea, Vomiting, Gastritis, Rash, Dizziness, Headache
Rare Vertigo, Acquired haemophilia
Very Rare Thrombotic Thrombocytopenic Purpura (TTP), Acute liver failure

Serious adverse reactions highlighted in regulatory documents include fatal bleeding events and Thrombotic Thrombocytopenic Purpura (TTP), a potentially fatal condition sometimes reported after short exposure.

Safety Restrictions and Contraindications

Official labeling defines specific restrictions for use:

  • Contraindications: Clopidogrel must not be used in individuals with active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) or known hypersensitivity to the medication.
  • Hepatic Impairment: It is contraindicated in severe hepatic impairment and requires caution in moderate hepatic disease.
  • Surgical Procedures: For elective surgery involving a major risk of bleeding, the medication is typically required to be discontinued 5–7 days prior to the procedure, according to regulatory guidelines.

Genetic factors are noted, as individuals classified as CYP2C19 poor metabolizers may have diminished antiplatelet effect and a higher risk for cardiovascular events. Patients should be monitored carefully for bleeding, particularly during the first weeks of treatment.

Overdose and Emergency Response

Clopid Overdose and When to Seek Help

Documented Overdose Manifestations

Overdose following the ingestion of an excessive amount of Clopidogrel may result in an intensification of its intended antiplatelet effect. The primary manifestation documented in regulatory labeling is a prolonged bleeding time, which can subsequently lead to serious bleeding complications. Officially reported severe outcomes that may affect the gastrointestinal system include gastrointestinal hemorrhage.


Emergency Response and Required Action

The official guidance strictly mandates contacting emergency services (911/Poison Control) immediately in cases of suspected overdose. Urgent medical attention is required for severe or life-threatening presentations, including if the affected person has collapsed, had a seizure, or is experiencing trouble breathing or if they cannot be awakened.


Management and Intervention Summary

Element Official Regulatory Statement
Overdose Risk Severe bleeding and life-threatening hemorrhage are noted as potential outcomes.
Antidote/Countermeasure Appropriate supportive therapy should be considered; platelet transfusion is documented as an intervention that may be used to restore clotting ability.

These official regulatory statements define the entire overdose profile by the risk of excessive bleeding, which strictly dictates the required actions of immediate contact with emergency services and the focus on documented countermeasure procedures.

Therapeutic Uses of Clopid

What Clopid Treats: Main Uses and Benefits

Clopidogrel is commonly used to help with managing symptoms associated with increased physiological stress across several cardiovascular and cerebrovascular domains. The medication is primarily applied in situations involving certain distressing symptoms linked to conditions where functional stability becomes affected in arteries, forming a core part of long-term supportive management.

Clopidogrel plays a role in managing the risk of recurrent manifestations in patients who have already experienced conditions like a heart attack (Myocardial Infarction), an ischemic stroke, or a Transient Ischemic Attack (TIA). It is considered relevant in managing acute phases, such as during unstable angina and following coronary artery stenting (PCI), as well as for chronic conditions like Peripheral Arterial Disease (PAD). The benefit provided is supportive relief that contributes to easing the overall symptom load and may assist with functional stability during periods of heightened risk.


Quick Fact: Relief for Vascular Stress
Common Scenarios Used after a heart attack, ischemic stroke, or TIA.
Primary Benefit Supports stability and helps manage the risk of recurrent manifestations.
Symptoms Addressed Addresses symptoms related to chronic or acute arterial obstruction.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult patients, including the elderly, who are managing conditions such as recent myocardial infarction, recent ischaemic stroke, established peripheral arterial disease, or acute coronary syndrome.

Populations for whom use is contraindicated: The medicine is strictly contraindicated for patients with active pathological bleeding, such as an active peptic ulcer or intracranial hemorrhage. It is also prohibited for patients with severe hepatic impairment or known hypersensitivity to the drug.

Age-related eligibility rules: Use is established only for the adult population. It is not recommended for the pediatric population (children and adolescents) as its safety and efficacy have not been formally established in this age group.

Condition-specific eligibility rules: Use with caution is required for patients with renal impairment or moderate hepatic impairment due to limited therapeutic experience. For patients who are CYP2C19 poor metabolizers, alternative treatment should be considered due to diminished drug response.

Pregnancy and lactation eligibility status: Use is not recommended during pregnancy or while breastfeeding.

Eligibility-related restrictions: Use cannot be recommended during the first 7 days following an acute ischaemic stroke. Regulatory labeling also requires discontinuation 7 days prior to any elective surgery associated with a major risk of bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official profile for Clopidogrel is defined by two primary types of interaction: those that diminish its effect and those that increase the risk of bleeding.


Reduced Antiplatelet Activity (Metabolic Interference)

Clopidogrel requires the CYP2C19 enzyme for conversion into its active form. Medicines that inhibit this enzyme can lead to significantly reduced antiplatelet activity. Regulatory agencies advise to avoid concomitant use of Clopidogrel with Omeprazole and Esomeprazole, as these proton pump inhibitors notably decrease the active drug levels.

This also applies to individuals with a specific genetic variation: the FDA label notes that patients identified as CYP2C19 Poor Metabolizers have a diminished response, which is a population-specific interaction consideration.

Increased Bleeding Risk (Pharmacodynamic Additivity)

Co-administering Clopidogrel with other agents that affect blood clotting can cause an additive pharmacodynamic effect, increasing the overall risk of bleeding.

Product Category Interacting Medicines Regulatory Classification
Anticoagulants Warfarin Increased risk of bleeding
Antiplatelet Agents Aspirin, Heparin Increased risk of bleeding
Pain Relievers Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of bleeding
Antidepressants SSRIs and SNRIs Increased risk of bleeding

Other Exposure Alterations

Clopidogrel's active metabolite is a potent inhibitor of the CYP2C8 enzyme. This interaction significantly raises the systemic exposure of other medicines cleared by this pathway, such as Repaglinide.

Mechanism of Action

Prodrug Bioactivation and Platelet Receptor Lock

Clopidogrel operates as an inactive prodrug, meaning it must be metabolized by the CYP2C19 enzyme in the liver to create its active form. This active metabolite then acts directly on platelets, achieving an irreversible blockade of the P2Y12 receptor by forming a permanent covalent bond. This unique binding mechanism initiates the mechanism of platelet function modulation by taking the primary receptor responsible for activation offline.


Disruption of ADP Signaling and Platelet Clumping

The physical blockage of the P2Y12 receptor prevents the platelet's natural activator, ADP, from transmitting its signal. This disruption leads to an increase in intracellular cAMP, which acts as a brake, suppressing the final activation of the GPIIb/IIIa receptor. The physiological consequence is a sustained functional inability of the treated platelets to change shape, release aggregating factors, or stick to one another, which limits the capacity for platelet aggregation.


Genetic and Time-Dependent Mechanism Constraints

The drug's necessary metabolic conversion is mechanistically constrained by the activity of the CYP2C19 enzyme; genetic variations can lead to reduced active metabolite formation and reduced saturation of the P2Y12 receptor, leading to diminished platelet inhibition. Furthermore, because the receptor blockade is permanent, the drug’s physiological action cannot be immediately reversed and persists until the body replaces all the affected platelets with new ones.

Dosage and Administration Information

How Clopid is Used: General Administration Guidelines

Clopidogrel is an antiplatelet agent administered through the oral route as a film-coated tablet. Its use follows standardized protocols that define specific dosing patterns and administration conditions, focusing on long-term management of established vascular conditions.

The medication is generally taken once daily, at approximately the same time each day, and may be administered with or without food. The film-coated tablet must be swallowed whole.


Labeled Dosing Regimens for Adults

Clopidogrel use is typically structured around an initial rapid-action dose followed by a long-term maintenance dose, based on the patient's clinical scenario:

Clinical Scenario Initial Dose Maintenance Dose
Acute Coronary Syndrome (ACS) Single 300 mg loading dose 75 mg once daily
Established Vascular Disease (MI, Stroke, PAD) None (or at physician discretion) 75 mg once daily

Population and Procedural Rules

Established protocols provide specific procedural guidance. For certain acute events in patients aged 75 years and older, clinical guidelines indicate that the 300 mg loading dose should be omitted, initiating treatment directly with 75 mg once daily. No established dosing is provided for children or adolescents.

If a dose is missed by less than 12 hours, it should be taken immediately. If more than 12 hours have elapsed, the missed dose should be skipped, and the regular schedule should be resumed, avoiding double doses. For elective surgery where antiplatelet activity must be reduced, discontinuation is often recommended 7 days prior to the procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clopidogrel

Evidence for Managing Established Vascular Conditions

Clopidogrel was studied for its application in long-term follow-up for individuals who have already experienced a serious vascular event. The research exploring this use included large-scale, long-term Randomized Controlled Trials (RCTs). These studies were applied in populations who had a confirmed history of either recent heart attack (Myocardial Infarction) or an ischemic stroke, or who had Established Peripheral Arterial Disease (PAD). The research measured outcomes related to the potential occurrence of new major vascular events over several years.

Findings describe patterns observed in the studies. In one key trial, the observed measurements of the combined major vascular outcome varied between the Clopidogrel group and the Aspirin group. This finding was described as having a greater magnitude in the subgroup of participants with Peripheral Arterial Disease (PAD). The research provides context but not individual predictions regarding long-term application in these conditions.

Evidence in Acute Coronary Syndrome (ACS)

Clopidogrel was evaluated in settings involving acute conditions such as Unstable Angina or Non-ST-Elevation Myocardial Infarction (NSTEMI). These studies were designed as large Placebo-Controlled Trials (RCTs) where participants received Clopidogrel or a placebo, with all participants also receiving background aspirin therapy. Research specifically examined outcomes related to physical discomfort and acute changes, such as the major composite endpoint of cardiovascular death, non-fatal MI, or stroke, in hospitalized adults.

The data show patterns related to the early and intermediate-term course of the condition. The observed measurements of the major composite outcome varied between the group that received Clopidogrel plus aspirin and the control group. This pattern was associated with the period where patients were considered to be in a phase of heightened symptom activity and physiological strain.

What the Research Landscape Shows and Where Gaps Exist

Overall, the evidence base for Clopidogrel included large-scale RCTs that were conducted to explore its application in specific vascular conditions. However, the evidence is limited regarding the clinical implications of genetic variations in patients, as research has identified a recognized variability in response tied to the CYP2C19 enzyme. Data for certain groups, such as pediatric populations or individuals with certain comorbidities, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Clopid (FAQ)


Q: What is the main difference between Clopid and a traditional blood thinner?

A: Clopidogrel (the active ingredient in Clopid) is classified as an antiplatelet agent, not a traditional anticoagulant (blood thinner). Its mechanism involves blocking specific receptors on platelets—small blood cells—to prevent them from sticking together. Traditional blood thinners often affect the body’s clotting factors, which is a different part of the overall clotting process.


Q: Is Clopid used to treat a heart attack or to prevent one?

A: Official product information states that Clopidogrel is indicated for the secondary prevention of serious vascular events like heart attack and ischemic stroke in adult patients who have already experienced one. It is also used in the management of Acute Coronary Syndrome (ACS), which includes certain types of heart attacks.


Q: How quickly does Clopid start working after the first pill is taken?

A: Clopidogrel begins to inhibit platelet aggregation from the first day it is taken. Regulatory documents indicate that the full, steady-state antiplatelet effect is typically achieved between Day 3 and Day 7 of consistent daily use.


Q: Are there any specific vitamins or supplements that are known to interact with Clopid?

A: While specific vitamins may not be explicitly listed in interaction warnings, official patient information advises telling your healthcare provider about all medications, herbs, and supplements you are taking. Regulatory warnings indicate that interactions with other products, including herbs and vitamins, are possible.


Q: Are there any known interactions between Clopid and common over-the-counter pain relievers like ibuprofen?

A: Yes, regulatory information warns that taking Clopidogrel with NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), which includes common pain relievers like ibuprofen, may lead to an increased risk of bleeding. This is because both medications can reduce the body's ability to clot blood effectively.


Q: What is the connection between Clopid and a metallic or changed sense of taste?

A: Official reports from post-marketing surveillance list taste disorders (also called dysgeusia or ageusia) as a reported adverse reaction. This indicates that some patients may experience a changed or metallic taste while taking the medication.


Q: Is it normal to bruise more easily while taking Clopid?

A: According to the official safety profile, hematoma (bruising) is listed as a Common adverse reaction. Because the drug affects blood clotting, patients may notice they bruise more easily.


Q: What are the most common non-serious side effects of Clopid?

A: The most common adverse reactions listed in official documents are diarrhea, abdominal pain, and hematoma (bruising). Patients are generally encouraged to report any unexpected effects to a healthcare provider.


Q: Can Clopid cause stomach pain or upset?

A: Yes, official safety information lists abdominal pain as a Common side effect. Other gastrointestinal issues like gastritis, nausea, and vomiting are also listed as Uncommon adverse reactions.


Q: Can Clopid cause confusion or dizziness?

A: Yes, dizziness is listed as an Uncommon adverse reaction in the official product documents. Furthermore, confusion has been listed among the Rare or Very Rare side effects reported during clinical experience.


Q: Does Clopid affect dental work or routine teeth cleaning?

A: It is important that patients inform their doctor and dentist that they are taking Clopidogrel before any dental procedure. While discontinuation is often necessary before major surgery, it is typically not recommended to stop the medication for routine dental work like cleanings or simple extractions.


Q: Is there a blood test to check if Clopid is working properly?

A: There is no single, routine blood test to confirm the drug’s effectiveness for all patients. Regulatory information highlights that the drug’s action is affected by the CYP2C19 enzyme, and patients identified as poor metabolizers may have a diminished response. Monitoring typically includes regular checks to manage the risk of bleeding.


Q: Is there a specific enzyme or gene that affects how Clopid works in some people?

A: Yes, official labeling notes that Clopidogrel is an inactive substance (a prodrug) that requires activation by the CYP2C19 enzyme in the liver. Patients who inherit specific genetic variations, leading them to be poor metabolizers, may have a reduced antiplatelet effect. This variability is noted in official drug labeling.


Q: Can people who have had a stroke or TIA benefit from long-term use of Clopid?

A: Clopidogrel is indicated for the secondary prevention of serious events in adult patients who have had a recent ischemic stroke. Regulatory and clinical guidance support its use as part of a long-term strategy to prevent future vascular events in these populations.


Q: What types of herbal remedies should be avoided while on Clopid?

A: Official patient safety information suggests discussing all herbal remedies with a healthcare provider. Herbal products, like some medications, can potentially interact with Clopidogrel and increase the risk of bleeding.


Q: How long does Clopid stay in the body after stopping the medication?

A: Clopidogrel's antiplatelet effect is irreversible because it permanently binds to receptors on the platelets. Therefore, the pharmacological action persists until the body replaces all the affected platelets, which typically takes between 7 to 10 days for full platelet function to return.


Q: Does Clopid interact with alcohol consumption?

A: While there is no explicit interaction listed for moderate alcohol use, regulatory sources indicate that consuming large amounts of alcohol may increase the risk of stomach bleeding. This combination carries a higher risk and is noted for caution in official warnings.


Q: Is the generic version of Clopid as effective as the brand-name version?

A: The FDA mandates that all generic drug products must be bioequivalent to their brand-name counterparts. This means that generic versions are required to work in the same way, deliver the same amount of active ingredient, and provide the same clinical benefit as the brand-name drug.


Q: Is there any evidence on the safety of Clopid during pregnancy or while breastfeeding?

A: Regulatory documents state that use of Clopidogrel is not recommended during pregnancy or while breastfeeding. It is currently not known if the drug passes into breast milk or if it will harm an unborn baby.


Q: What signs might indicate a liver problem while taking Clopid?

A: The official safety profile lists Acute Liver Failure as a Very Rare adverse reaction. Due to the risk of liver adverse reactions, the medication is contraindicated in severe liver impairment. Liver function may be monitored in individuals with existing liver conditions.


Q: Is there a link between Clopid and joint or muscle pain?

A: Official product information lists joint pain ( arthralgia) and muscle pain ( myalgia) as Uncommon adverse reactions. This indicates that these types of pain have been reported, but they are not among the most frequently observed side effects.


Q: Does Clopid reduce the risk of blood clots from atrial fibrillation (off-label curiosity)?

A: Official therapeutic indications from some regulatory authorities include a specific patient group with atrial fibrillation who are unable to take Vitamin K antagonists and have a low bleeding risk. In these cases, it may be used in combination with aspirin.


Q: Is it normal to have small red or purple spots on the skin (petechiae) while taking Clopid?

A: Small red or purple spots on the skin (known as petechiae or purpura) are related to bleeding disorders and are listed as an Uncommon adverse reaction in regulatory documents. While not one of the most frequent side effects, it is a documented occurrence related to the drug's antiplatelet action.

How should Clopid be stored and disposed of?

How to Store and Dispose of Clopidogrel

Clopidogrel tablets must be stored according to regulatory requirements to maintain product integrity and safety.


Official Storage Conditions

  • Temperature: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief excursions are permitted between 15 C and 30 C.
  • Protection: The medicine must be kept in its original container to protect it from moisture.
  • Child Safety: All Clopidogrel tablets must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Clopidogrel must be handled according to local requirements. The regulatory mandate specifies that the product should not be disposed of via household waste or wastewater to prevent environmental harm. Disposal must follow procedures established by local authorities or return-to-pharmacy programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clopid found in:

A-Z Index: